NCT03258567View on ClinicalTrials.gov

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

June 1, 2029

Study Completion Date

June 1, 2031

Conditions
Epstein-Barr Virus InfectionsLymphomaLymphoproliferative DisorderDisorders, Lymphoproliferative
Interventions
BIOLOGICAL

Nivolumab

Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH